In a landmark move during the Union Budget 2026-27, Finance Minister Nirmala Sitharaman announced the launch of Biopharma Shakti, a five-year program aimed at positioning India as a global biopharmaceutical hub. The initiative comes with a proposed outlay of ₹10,000 crore, underlining the government’s commitment to building a robust, self-reliant healthcare and life sciences ecosystem.
Strengthening India’s Biopharma Ecosystem
Biopharma Shakti focuses on enhancing India’s capabilities in biologics, biosimilars, and innovative pharmaceuticals. By developing infrastructure, research facilities, and manufacturing capacities, the program aims to reduce import dependence and strengthen domestic production of critical therapies.
The initiative is also designed to meet rising domestic demand driven by the growing prevalence of non-communicable diseases, including diabetes, cancer, and autoimmune disorders, while expanding India’s footprint in global pharmaceutical markets.
Research, Innovation, and Clinical Trials at the Core
A key component of Biopharma Shakti is the emphasis on research and innovation. The program seeks to expand national institutions dedicated to pharmaceutical education and R&D, along with the establishment of a network of over 1,000 accredited clinical trial sites, positioning India as a global hub for drug development and clinical research.
Boosting Healthcare Access and Employment
By integrating technology, innovation, and scientific expertise, Biopharma Shakti is expected to enhance healthcare accessibility, create high-value employment opportunities, and strengthen India’s competitiveness as a trusted supplier of quality biopharmaceutical products.
Expert Insights
According to Dr. Sameer Bhati, a public health analyst, “The Biopharma Shakti initiative is a strategic intervention for India’s pharmaceutical sector. It is poised to enhance domestic research capabilities, strengthen biologics and biosimilars production, and reduce reliance on imports for critical therapies.”
The program underscores the government’s vision of self-reliance in healthcare while positioning India as a global leader in biopharmaceutical innovation over the next five years.